Another step forward in the wide-scale deployment of the salivabased test in France and on international markets.

“On November 27th, 2020, France’s Haute Autorité de Santé (HAS) issued a favourable opinion on the usage and reimbursement of the EasyCOV test on symptomatic patients for whom nasal swabbing is impossible or difficult to perform. The consortium behind the test, comprising the biotech company SKILLCELL (ALCEN Group), the laboratory SYS2DIAG (CNRS/ALCEN) and the company VOGO, are pleased with these initial indications which could be further expanded.

Given this positive decision, EasyCOV is now fully recognised as a relevant tool in strategies to diagnose and detect COVID-19. This new milestone will help accelerate the commercial roll-out of the test in France and on international markets.”

For more information, the full press release.